Gene expression-based assays, such as OncotypeDx Recurrence Score, Mammaprint, Endopredict, and Prosigna can be used to gain additional prognostic and/or predictive information regarding the benefit of adjuvant CT in early HR-positive and HER2-negative BC (I, A) (Table 2). The gene discussed is ERBB2; the disease is breast cancer.